Award Number: W81XWH-04-1-0012

TITLE: Generation of Transgenic Animals Producing Ezymatically Active Prostate-Specific Antigen (PSA) in Normal and Malignant Prostate Tissue

PRINCIPAL INVESTIGATOR: Samuel R. Denmeade, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205

REPORT DATE: February 2005

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050630 037

Public reporting burden for this collection of info	REPORT DOCUMENTATION PAGE			DMB No. 074-0188	
the data needed, and completing and reviewing reducing this burden to Washington Headquarte Management and Budget, Paperwork Reductior	rmation is estimated to average 1 hour per response, this collection of Information. Send comments regarc rs Services, Directorate for Information Operations ar Project (0704-0188), Washington, DC 20503	including the time for reviewing in ling this burden estimate or any of ad Reports, 1215 Jefferson Davis	structions, searching ther aspect of this coll Highway, Suite 1204,	existing data sources, gathering and maintaining action of information, including suggestions for Arlington, VA 22202-4302, and to the Office of	
1. AGENCY USE ONLY	ENCY USE ONLY 2. REPORT DATE 3. REPORT TYPE AND DATE		DATES COVER	RED	
(Leave blank)	February 2005	Final (1 Feb 2	2004 – 31 Jan 2005)		
4. TITLE AND SUBTITLE			5. FUNDING	NUMBERS	
Seneration of Transgenic Animals Producing Ezymatically			W81XWH-04-1-0012		
Malignant Prostate Ti	ssue	mai ana	, j		
			l '		
6. AUTHOR(S)			-	• f	
Samuel R. Denmeade. M	.D.	• .			
· · · · · · · · · · · · · · · · · · ·					
	NAME (S) AND ADDRESS(ES)				
Johns Hopkins University			REPORT NUMBER		
School of Medicine					
Baltimore, MD 21205					
F-Mail: denmessehml od	,		· ·		
	••		10 000100		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			AGENCY REPORT NUMBER		
U.S. Army Medical Research and Materiel Command					
Fort Detrick, Maryland 21702-5012					
		· ·			
11 SUPPLEMENTARY NOTES			1	-	
12a. DISTRIBUTION / AVAILABILI Approved for Public Re	TY STATEMENT elease; Distribution Unl	imited		12b. DISTRIBUTION CODE	
12a. DISTRIBUTION / AVAILABILI Approved for Public Re	TY STATEMENT elease; Distribution Unl	imited		12b. DISTRIBUTION CODE	
12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W	TY STATEMENT elease; Distribution Unl ords)	imited		12b. DISTRIBUTION CODE	
12a. DISTRIBUTION / AVAILABILI Approved for Public Ro 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (ry statement elease; Distribution Unl ords) PSA) is used extensively as a s	imited erum marker to scre	en for prosta	12b. DISTRIBUTION CODE	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f	imited erum marker to scre for prostate cancer.	en for prosta	te cancer and is also gic role of PSA in	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea	imited erum marker to scre or prostate cancer. ars to play a role in 1	en for prosta The physiolo reproduction	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. AESTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marked normal prostate biology is motility. PSA is a serine p 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like	imited erum marker to scre for prostate cancer. f ars to play a role in r e specificity. PSA, t	en for prosta The physiolo reproduction hrough its pr	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is motility. PSA is a serine p play an important role in p 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv	imited erum marker to scre for prostate cancer. ars to play a role in n e specificity. PSA, t asion, angiogenesis,	en for prosta The physiolo reproduction hrough its pr , and/or meta	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal	imited erum marker to scre for prostate cancer. ars to play a role in r e specificity. PSA, t asion, angiogenesis, kes large amounts o	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc	imited erum marker to scree for prostate cancer. for ars to play a role in r e specificity. PSA, t asion, angiogenesis, ces large amounts of ressing of, Pro-PSA	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the neces 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre	imited erum marker to scre for prostate cancer. ars to play a role in r e specificity. PSA, t asion, angiogenesis, ces large amounts of sessing of, Pro-PSA ently available prost	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer co	te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete processary processing protease. Current tically inactive PSA are not use	imited erum marker to scre for prostate cancer. ars to play a role in r e specificity. PSA, t asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available prost ful for developing t	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer co hese prodrug	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Re 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of I 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Current tically inactive PSA are not use PSA in the biology of prostate of	imited erum marker to scree for prostate cancer. for ars to play a role in re e specificity. PSA, t asion, angiogenesis, ces large amounts of cessing of, Pro-PSA ently available prost eful for developing t cancer. We have gen	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer co hese prodrug ierated a mod	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of I was used to generate cell 1 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher	imited erum marker to scre for prostate cancer. The erum marker to scree for prostate cancer. The erum arole in the especificity. PSA, the asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available proster ful for developing the ancer. We have gen levels of total PSA a	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer ce hese prodrug lerated a mod and most of t	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marker normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of F was used to generate cell 1 enzymatically active. This 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher s PSA gene was used to generat	imited erum marker to scre for prostate cancer. ars to play a role in r e specificity. PSA, t asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available prost ful for developing t ancer. We have gen levels of total PSA a re mice that produce	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer co hese prodrug herated a mod and most of t	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of I was used to generate cell 1 enzymatically active. This can be used to study role o 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher s PSA gene was used to generat of PSA in biology of prostate ca	imited erum marker to scree for prostate cancer. ars to play a role in re especificity. PSA, to asion, angiogenesis, kes large amounts of essing of, Pro-PSA ently available prost ful for developing to ancer. We have gen levels of total PSA a re mice that produce ncer and to test PSA	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer ce hese prodrug nerated a mod and most of t PSA in their A-activated p	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice rodrug therapies.	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. AESTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate marked normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of H was used to generate cell 1 enzymatically active. This can be used to study role o 14. SUBJECT TERMS 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher s PSA gene was used to generat of PSA in biology of prostate ca	imited erum marker to scree for prostate cancer. The ars to play a role in the especificity. PSA, the asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available proster ful for developing the cancer. We have gen levels of total PSA are mice that produce ncer and to test PSA	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer co hese prodrug herated a mod and most of t PSA in their A-activated p	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice rodrug therapies.	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of I was used to generate cell 1 enzymatically active. This can be used to study role o 14. SUBJECT TERMS 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher s PSA gene was used to generat of PSA in biology of prostate ca	imited erum marker to scree for prostate cancer. The ars to play a role in re- especificity. PSA, the asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available prost ful for developing the ancer. We have gen levels of total PSA are mice that produce ncer and to test PSA	en for prosta The physiolo reproduction hrough its pr , and/or meta f enzymatica to the active tate cancer ce hese prodrug herated a mod and most of t PSA in their A-activated p	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice rodrug therapies. 15. NUMBER OF PAGES 8	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the necess models producing enzyma understanding the role of I was used to generate cell 1 enzymatically active. This can be used to study role o 14. SUBJECT TERMS Protease, PSA, mouse ref 	ry statement elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv. a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Current tically inactive PSA are not use PSA in the biology of prostate co ines that produce much higher s PSA gene was used to generat f PSA in biology of prostate ca	imited erum marker to scree for prostate cancer. The ars to play a role in the especificity. PSA, the asion, angiogenesis, ces large amounts of tessing of, Pro-PSA ently available prost ful for developing the ancer. We have gen levels of total PSA are mice that produce ncer and to test PSA	en for prosta The physiolo reproduction hrough its pr and/or meta f enzymatica to the active tate cancer co hese prodrug ierated a mod and most of t PSA in their A-activated p	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice rodrug therapies. 15. NUMBER OF PAGES 8 16. PRICE CODE	
 12a. DISTRIBUTION / AVAILABILI Approved for Public Ref 13. ABSTRACT (Maximum 200 W Prostate-specific antigen (used as a surrogate market normal prostate biology is motility. PSA is a serine p play an important role in p has successfully produced inactivity appears to be du to the absence of the neces models producing enzyma understanding the role of H was used to generate cell 1 enzymatically active. This can be used to study role o 14. SUBJECT TERMS Protease, PSA, mouse r 17. SECURITY CLASSIFICATION OF REPORT 	ry STATEMENT elease; Distribution Unl ords) PSA) is used extensively as a s r to assess response to therapy f uncertain but the protein appea protease with chymotrypsin-like prostate cancer progression, inv. a mammalian cell line that mal e to lack of, or incomplete proc ssary processing protease. Curre tically inactive PSA are not use PSA in the biology of prostate c ines that produce much higher s PSA gene was used to generat of PSA in biology of prostate ca model 18. SECURITY CLASSIFICATION OF THIS PAGE	imited erum marker to scree for prostate cancer. The ars to play a role in the especificity. PSA, the asion, angiogenesis, ces large amounts of essing of, Pro-PSA ently available prost ful for developing the ancer. We have gen levels of total PSA are mice that produce ncer and to test PSA	en for prosta The physiolo reproduction hrough its pr and/or meta f enzymatica to the active tate cancer co hese prodrug herated a mod and most of t PSA in their A-activated p	12b. DISTRIBUTION CODE te cancer and is also gic role of PSA in by enhancing sperm oteolytic activity, may stasis. To date, no lab lly active PSA. This form, presumably due ell lines and mouse therapies or for lified PSA gene that his PSA is r prostates. These mice rodrug therapies. 15. NUMBER OF PAGES 8 16. PRICE CODE 20. LIMITATION OF ABSTRACT	

NSN 7540-01-280-5500

|

-

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments	7
Reportable Outcomes/References	7
Conclusions	8

INTRODUCTION:

Prostate-specific antigen (PSA) is used extensively as a serum marker to screen for prostate cancer and is also used as a surrogate marker to assess response to therapy for prostate cancer. The physiologic role of PSA in normal prostate biology is uncertain but the protein appears to play a role in reproduction by enhancing sperm motility. PSA is a serine protease with chymotrypsin-like specificity. PSA, through its proteolytic activity, may play an important role in prostate cancer progression, invasion, angiogenesis, and/or metastasis. The PSA protein is secreted as an inactive zymogen and a 7 amino acid "Pro" sequence must be correctly processed to generate enzymatically active PSA. To date, no lab has successfully produced a mammalian cell line that makes large amounts of enzymatically active PSA. This inactivity appears to be due to lack of, or incomplete processing of, Pro-PSA to the active form, presumably due to the absence of the necessary processing protease. Our laboratory and others are developing prodrugs that are activated by PSA. Other groups are interested in studying the role of enzymatically active PSA in prostate tumor growth, progression, angiogenesis, and metastasis. Currently available prostate cancer cell lines and mouse models producing enzymatically inactive PSA are not useful for developing these prodrug therapies or for understanding the role of PSA in the biology of prostate cancer. The underlying hypothesis of our proposal was that a modified PSA gene can be engineered that will yield a PSA protein that will be correctly processed to enzymatically active PSA both in vitro and in vivo. Through site directed mutagenesis we have removed the 21 nucleotides coding for the 7amino acid wild type Pro-PSA sequence and replaced them with the coding sequence that generates the amino acid sequence recognized by furin, a ubiquitously expressed protease. This modified PSA gene will be used to produce a transgenic mouse model that makes enzymatically active PSA in its prostate. The wild type PSA gene will also be used to make a second transgenic mouse and expression of active PSA in these two models will be compared. These cell lines and mouse models that can be used in development of PSA-activated prodrug therapies and can also be used to study role of enzymatically active PSA in biology of prostate cancer.

Body:

The goal of this Exploration: Resource Development award was to generate cell lines and transgenic animals that produce increased amounts of enzymatically active PSA compared to available PSA-producing prostate cancer models. **Task 1** was to characterize the enzymatic activity of clones from Pre-Pro PSA and Pre-Pro"Furin" PSA transfected prostate cancer cell lines.

For this task we generated two PSA constructs. One of these consisted of the wild type Pre-Pro-PSA sequence and the second consisted of a construct in which the Pro portion of the sequence was replaced with a sequence that encoded for a polypeptide recognized as a substrate for the ubiquitously expressed furin protease. These constructs were transfected into the human prostate cancer cell lines CWR22R, LNCaP and PC-3. Previously we had demonstrated that CWR22R produced low levels of PSA in vitro with less than 15% of this PSA being enzymatically active. LNCaP cells produce higher amounts of PSA, but again we have demonstrated that only ~ 15% of this PSA was active.

We have generated clones of LNCaP, and CWR22R expressing both the wild type and mutant PSA genes. PC-3 cells have also been transfected and are currently being characterized. Figure 1 shows representational data on relative production of PSA in a CWR22R clones. These results demonstrate that both wild type and mutant transfected clones produce about 10-fold higher amounts of PSA than the untransfected wild type CWR22R. In addition, the cells transfected with the mutant PSA produce about 70-fold higher amount of active PSA compared to the untransfected wild type. The cell transfected to overexpress wild type PSA generate more PSA than the untransfected wild type, but both cell types only produce a low percentage of active PSA.



Figure 1. Relative production of total PSA and enzymatically active PSA by wild type (untransfected) CWR22R cells compared to Pre-Pro(wt)-PSA and Pre-Pro(Furin)-PSA transfected CWR22R cells. PSA produced by wild type scaled to 1 relative unit. PSA from wild type CWR22R cells was 16% active, Pre-Pro(wt)-PSA was 11% active and Pre-Pro(Furin)-PSA was 99% active compared to enzymatically active PSA purified from human seminal plasma.

Clones of both wild type and mutant transfected LNCaP and CWR22R were evaluated for effects of increased expression of active PSA on growth. In both cases no significant change in growth rates were observed between the two sets of clones (data not shown). In addition growth rate of CWR22R untransfected wild type and CWR22R mutant PSA transfected were compared in vivo when inoculated subcutaneously. These experiments demonstrated no significant difference in tumor doubling times between the two lines (data not shown). Overall these results suggest that increased production of enzymatically active PSA does not change growth rate of cells in vivo or in vivo when growing subcutaneously. Further experiments are underway in our laboratory to assess effects of enhanced production of active PSA on growth of tumors within the prostate and within the bone.

Task 2 of the award was to produce transgenic animals expressing either Pre-Pro"Furin" PSA or Pre-ProPSA gene under control of androgen regulated prostate-specific probasin promoter. To accomplish this we cut Pre-Pro PSA and Pre-Pro "furin" PSA gene out of pcDNA3.1 vector and reinserted it downstream of (ARR)₂ probasin promoter in pGL2-Basic Vector. The linearized gene was provided to the Johns Hopkins Transgenic Animal Core Facility which provided us with founder animals expressing either of each construct.

The Core Facility initially provided us with animals expressing wild type PSA. Through serial crossing we have been able to generate animals that are homozygous for PSA production in the prostate, figure 2. Prostates from these animals have been isolated and total PSA produced determined from homogenates. Levels of PSA produced are in the 1-2 μ g/ml range which is approximately 100-fold lower than those observed for human prostate. Greater than 95% of this PSA was in the free (i.e. uncomplexed) form. Mixing the PSA isolated from these prostates with the PSA inhibitor alpha-2-macroglobulin demonstrated that some fraction of this PSA was enzymatically active, figure 2 (white arrows). Following immunoprecipitation of PSA from these homogenates, incubation with a PSA-selective fluorescent substrate demonstrated the percent enzymatic activity to be ~ 15%.



Figure 2. Western blot analysis of PSA produced by Pre-Pro(wt)-PSA mouse. Black arrows show 33 kDa PSA and PSA-A2M complex. White arrows indicate increased density of PSA-A2M band following incubation of prostate homogenate with purified human A2M.

At the same time these animals were being developed a series of Pre-Pro"Furin" PSA founder animals were also identified. These animals were crossed with wild type animals x 2 and none of ~ 20 offspring were positive for the PSA gene. These results suggested that the original founders did not have PSA in the germline. Recently a second set of founder animals were generated by the transgenic core facility. These animals have been crossed with wild type and we have identified progeny that are positive for PSA by PCR-analysis. We are currently waiting for these animals to mature and plan to characterize the amount of PSA produced as well as the percent enzymatic activity in order to confirm whether our original hypothesis will be true. Subsequently, these wild type and mutant PSA-producing animals will be characterized for effects of PSA expression on prostate morphology. Animals will also be crossed with various prostate cancer mouse models (i.e. TRAMP, c-myc, SKP-2) to determine if PSA expression in these cancers changes morphology, growth rate, and metastatic potential.

Key Accomplishments:

- 1. Generated PSA construct that yields cell lines that produce high levels of enzymatically active PSA.
- 2. Generated PSA-producing transgenic mouse that produces relatively high levels of PSA in the prostate. However, only small percentage of PSA produced by this mouse is enzymatically active
- 3. Generated mutant PSA-producing transgenic mouse that will potentially produce high levels of enzymatically active PSA in prostate

Reportable Outcomes:

- 1. Generated cell lines producing high levels of enzymatically active PSA that will be made available to prostate cancer research community.
- 2. Generated PSA-producing transgenic mice that will be made available to the prostate cancer research community.
- 3. Post-Doctoral Fellow Dr. Simon Williams awarded DOD PCRP Post-Doctoral Fellow Award based on this work.
- 4. Applied for DOD PCRP Idea Development Award (2/05) to support further characterization of these transgenic animals and effect of PSA-production on prostate cancer growth and metastases.

References:

- 1. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate. 2001 Jun 15; 48(1):1-6.
- 2. Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hk2, but not pro PSA, involves autoprocessing. Prostate. 2001 Jul 1;48(2):122-6.
- 3. Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2459-61.
- 4. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hk2, and PSMA in human prostate cancer models. Prostate. 2003 Mar 1;54(4):249-57.
- 5. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate. 2003 Jun 15;56(1):45-53.
- 6. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000.

Conclusions:

١

A more relevant prostate cancer model would be one that produces higher amounts of enzymatically active PSA at levels that approach those produced by human prostate cancers. In the twelve months of support from this award we have generated such improved PSA-producing cell lines. In addition, we have generated transgenic animals that produce PSA in the prostate that could be used to characterize role of PSA in prostate cancer biology, develop new vaccine strategies and test PSA-activated prodrug/protoxin therapies.